1 Sergio Juárez-Méndez, A. Z.-D., Vanessa Villegas-Ruíz,Oscar Alberto Pérez-González,Mauricio Salcedo, Ricardo López-Romero, Edgar Román-Basaure, Minerva Lazos-Ochoa,Víctor Edén Montes de Oca-Fuentes,4 Guelaguetza Vázquez-Ortiz,and José Moreno. Splice variants of zinc finger protein 695 mRNA associated to ovarian cancer. journal of Ovarian Research 6, 1-10 (2013).
2 Rojas, V., Hirshfield, K. M., Ganesan, S. & Rodriguez-Rodriguez, L. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci17, doi:10.3390/ijms17122113 (2016).
3 Zhu, J., Chen, Z. & Yong, L. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol148, 368-374, doi:10.1016/j.ygyno.2017.11.028 (2018).
4 Lin, J. C. Impacts of Alternative Splicing Events on the Differentiation of Adipocytes. Int J Mol Sci16, 22169-22189, doi:10.3390/ijms160922169 (2015).
5 Bonnal, S., Vigevani, L. & Valcárcel, J. The spliceosome as a target of novel antitumour drugs. Nature Reviews Drug Discovery11, 847-859, doi:10.1038/nrd3823 (2012).
6 de Miguel, F. J. et al. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res74, 1105-1115, doi:10.1158/0008-5472.CAN-13-1481 (2014).
7 Padgett, R. A. New connections between splicing and human disease. Trends Genet28, 147-154, doi:10.1016/j.tig.2012.01.001 (2012).
8 Pajares, M. J. et al. Alternative splicing: an emerging topic in molecular and clinical oncology. The Lancet Oncology8, 349-357, doi:10.1016/s1470-2045(07)70104-3 (2007).
9 Ye, Z. S. et al. Survival-associated alternative splicing events interact with the immune microenvironment in stomach adenocarcinoma. World J Gastroenterol27, 2871-2894, doi:10.3748/wjg.v27.i21.2871 (2021).
10 Frankiw, L., Baltimore, D. & Li, G. Alternative mRNA splicing in cancer immunotherapy. Nat Rev Immunol19, 675-687, doi:10.1038/s41577-019-0195-7 (2019).
11 Brosseau, J. P. et al. Tumor microenvironment-associated modifications of alternative splicing. Rna20, 189-201, doi:10.1261/rna.042168.113 (2013).
12 Ergun, A. et al. Differential splicing across immune system lineages. Proceedings of the National Academy of Sciences of the United States of America110, 14324-14329, doi:10.1073/pnas.1311839110 (2013).
13 Martinez-Montiel, N., Rosas-Murrieta, N. H., Anaya Ruiz, M., Monjaraz-Guzman, E. & Martinez-Contreras, R. Alternative Splicing as a Target for Cancer Treatment. Int J Mol Sci19, doi:10.3390/ijms19020545 (2018).
14 Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A. & Skotheim, R. I. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene35, 2413-2427, doi:10.1038/onc.2015.318 (2016).
15 Liu, X. et al. Identification of Tumor Microenvironment-Related Alternative Splicing Events to Predict the Prognosis of Endometrial Cancer. Front Oncol11, 645912, doi:10.3389/fonc.2021.645912 (2021).
16 Wang, L. et al. Prognostic alternative splicing signature reveals the landscape of immune infiltration in Pancreatic Cancer. J Cancer11, 6530-6544, doi:10.7150/jca.47877 (2020).
17 Klinck, R. et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res68, 657-663, doi:10.1158/0008-5472.CAN-07-2580 (2008).
18 Song, J. et al. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma. J Cell Physiol234, 22753-22764, doi:10.1002/jcp.28840 (2019).
19 Charoentong, P. et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep18, 248-262, doi:10.1016/j.celrep.2016.12.019 (2017).
20 Xie, Z. C., Wu, H. Y., Dang, Y. W. & Chen, G. Role of alternative splicing signatures in the prognosis of glioblastoma. Cancer Med8, 7623-7636, doi:10.1002/cam4.2666 (2019).
21 Sun, J. R. et al. Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma. Front Genet11, 796, doi:10.3389/fgene.2020.00796 (2020).
22 Shao, X. Y., Dong, J., Zhang, H., Wu, Y. S. & Zheng, L. Prognostic Value and Potential Role of Alternative mRNA Splicing Events in Cervical Cancer. Front Genet11, 726, doi:10.3389/fgene.2020.00726 (2020).
23 Chen, P. et al. Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Endometrial Cancer. Front Genet11, 456, doi:10.3389/fgene.2020.00456 (2020).
24 Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun4, 2612, doi:10.1038/ncomms3612 (2013).
25 Shen, S., Wang, Y., Wang, C., Wu, Y. N. & Xing, Y. SURVIV for survival analysis of mRNA isoform variation. Nat Commun7, 11548, doi:10.1038/ncomms11548 (2016).
26 Oltean, S. & Bates, D. O. Hallmarks of alternative splicing in cancer. Oncogene33, 5311-5318, doi:10.1038/onc.2013.533 (2014).
27 Fan, Y. C., Min, L., Chen, H. & Liu, Y. L. Alternative splicing isoform of T cell factor 4K suppresses the proliferation and metastasis of non-small cell lung cancer cells. Genet Mol Res14, 14009-14018, doi:10.4238/2015.October.29.20 (2015).
28 Paronetto, M. P., Passacantilli, I. & Sette, C. Alternative splicing and cell survival: from tissue homeostasis to disease. Cell Death Differ23, 1919-1929, doi:10.1038/cdd.2016.91 (2016).
29 Calabretta, S. et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene35, 2031-2039, doi:10.1038/onc.2015.270 (2016).
30 Dutta, P. et al. EVI1 splice variants modulate functional responses in ovarian cancer cells. Mol Oncol7, 647-668, doi:10.1016/j.molonc.2013.02.008 (2013).
31 Sosulski, A. et al. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS One11, e0156595, doi:10.1371/journal.pone.0156595 (2016).
32 Wu, Z. et al. Alternative splicing implicated in immunity and prognosis of colon adenocarcinoma. Int Immunopharmacol89, 107075, doi:10.1016/j.intimp.2020.107075 (2020).
33 Hoyos, L. E. & Abdel-Wahab, O. Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens. Cancer Cell34, 181-183, doi:10.1016/j.ccell.2018.07.008 (2018).
34 Schadendorf, D. et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol33, 1889-1894, doi:10.1200/JCO.2014.56.2736 (2015).
35 Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. 348, 69-74, doi:10.1126/science.aaa4971 %J Science (2015).